Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor α biologics and switched to ustekinumab

British Journal of Dermatology

Volumn 163, Issue 2, 2010, Pages 433-434

  Downs, A M R ^a  

^a ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

psoriasis; ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH HAZARD; HUMAN; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE INDEX; SIDE EFFECT; ULCERATIVE COLITIS; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PSORIASIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954882667     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09832.x     Document Type: Letter

References (11)

1. Leonardi CL, Kimball AB, Papp KA et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 371 : 1665 1674.
2. Papp KA, Langley RG, Lebwohl M et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 371 : 1675 1684.
3. Smith CH, Anstey AV, Barker JNWN et al. British Assosiation of Dermatologists guidelines for biologics intervention for psoriasis. Br J Dermatol 2009 161 : 987 1019.
4. Downs AM. Switching between anti tumour necrosis factor agents - is patient weight an important consideration? Br J Dermatol 2009 160 : 1123 1134.
5. Gisondi P, Cotena C, Tessari G et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008 22 : 341 344.
6. Saraceno R, Schipani C, Mazzotta A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008 57 : 290 295.
7. Esposito M, Mazzotta A, Saraceno R et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009 22 : 219 225.
8. Warner JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003 177 : 351 355.
9. Cathorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008 582 : 117 131.
10. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008 135 : 1130 1141.
11. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 : 633 640.